Search

Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India

Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India. Click here to find out and learn more.

Jardiance® (empagliflozin) now approved in India for treatment of chronic kidney disease

Jardiance® (empagliflozin) now approved in India

Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug

Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug.

Boehringer Ingelheim announces appointment of Vani Manja as India Country MD

Boehringer Ingelheim has announced that Vani Manja is appointed Country Managing Director for India. Read the press release here and find out more.

1988-2015

Following the death of Hubertus Liebrecht (1991), the owning family made some fundamental decisions regarding the company’s alignment. Learn more here.

About Us

Human Health